Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News NAYA Biosciences Inc NAYA

Healthcare Medical Devices
NAYA Biosciences, Inc. formerly INVO Bioscience, Inc. operates the fertility business, as well as its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NAYA)

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire 18 hours ago

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

GlobeNewswire 7 days ago

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

GlobeNewswire 10 days ago

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

GlobeNewswire October 14, 2024

INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

GlobeNewswire August 14, 2024

INVO Reports Record First Quarter 2024 Financial Results

GlobeNewswire May 15, 2024

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire April 16, 2024

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK(TM) Bispecific Antibody in the American Society of Hematology's Blood Journal

PR Newswire December 11, 2023

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK(TM) Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

PR Newswire December 6, 2023
View More News ››

Opinion & Analysis (NDAQ:NAYA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NAYA)

INVO Bioscience and NAYA Biosciences Close Merger,&#xA0;Comb

NEWS: $INVO INVO Bioscience and NAYA Biosciences Close Merger,&#xA0;Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA...
whytestocks - October 14, 2024

INVO.....on watch.....still uh huh

70 pesos
Iseneschal - September 13, 2024

INVO.....still say this is ripe ; )

Expecting the unexpected Start the "drumroll"
Iseneschal - August 26, 2024

INVO......this is trading very strange

Seems to be people starting to reach for positions and there was a 75K share trade over 90 cents.....then the next trade shows 81 cents ...
Iseneschal - August 21, 2024

INVO update....... Bouncing off low post ER

On watch....88 cents
Iseneschal - August 20, 2024

RE:INVO.....N.H.O.D

It took 2 weeks almost to catch a breeze ; ) $1.09 now and thru DTL
Iseneschal - August 13, 2024
View more Bullboard ››

Safe Supply Streaming Co Ltd.

Safe Supply Streaming Co Ltd.

Safe Supply Streaming Co Ltd. is engaged in investing in the legal and regulated supply of drugs. The Company’s focus is ...
View More »